Asunaprevir	B:C3491974
:	O
An	O
HCV	O
Protease	I:C4049839
Inhibitor	I:C4049839
With	O
Preferential	O
Liver	O
Distribution	O
.	O

Asunaprevir	O
:	O
An	O
HCV	B:C4049839
Protease	I:C4049839
Inhibitor	I:C4049839
With	O
Preferential	O
Liver	O
Distribution	O
.	O

Asunaprevir	O
:	O
An	O
HCV	O
Protease	I:C4049839
Inhibitor	I:C4049839
With	O
Preferential	O
Liver	B:C0023884
Distribution	O
.	O

Asunaprevir	O
:	O
An	O
HCV	O
Protease	I:C4049839
Inhibitor	I:C4049839
With	O
Preferential	O
Liver	O
Distribution	B:C1378698
.	O

Asunaprevir	B:C3491974
is	O
an	O
inhibitor	O
of	I:C4049839
the	I:C4049839
hepatitis	I:C4049839
C	I:C4049839
virus	I:C4049839
(	I:C4049839
HCV	I:C4049839
)	I:C4049839
NS3	I:C4049839
/	I:C4049839
4A	I:C4049839
protease	I:C4049839
,	O
demonstrating	O
efficacy	O
in	O
clinical	O
studies	I:C0008972
in	O
patients	O
infected	O
with	O
HCV	O
genotype	I:C3532919
1	I:C3532919
or	O
4	O
,	O
with	O
either	O
peginterferon	O
/	O
ribavirin	O
or	O
combinations	O
of	O
direct	O
-	O
acting	O
antivirals	O
.	O

Asunaprevir	O
is	O
an	O
inhibitor	B:C4049839
of	I:C4049839
the	I:C4049839
hepatitis	I:C4049839
C	I:C4049839
virus	I:C4049839
(	I:C4049839
HCV	I:C4049839
)	I:C4049839
NS3	I:C4049839
/	I:C4049839
4A	I:C4049839
protease	I:C4049839
,	O
demonstrating	O
efficacy	O
in	O
clinical	O
studies	I:C0008972
in	O
patients	O
infected	O
with	O
HCV	O
genotype	I:C3532919
1	I:C3532919
or	O
4	O
,	O
with	O
either	O
peginterferon	O
/	O
ribavirin	O
or	O
combinations	O
of	O
direct	O
-	O
acting	O
antivirals	O
.	O

Asunaprevir	O
is	O
an	O
inhibitor	O
of	I:C4049839
the	I:C4049839
hepatitis	I:C4049839
C	I:C4049839
virus	I:C4049839
(	I:C4049839
HCV	I:C4049839
)	I:C4049839
NS3	I:C4049839
/	I:C4049839
4A	I:C4049839
protease	I:C4049839
,	O
demonstrating	O
efficacy	O
in	O
clinical	B:C0008972
studies	I:C0008972
in	O
patients	O
infected	O
with	O
HCV	O
genotype	I:C3532919
1	I:C3532919
or	O
4	O
,	O
with	O
either	O
peginterferon	O
/	O
ribavirin	O
or	O
combinations	O
of	O
direct	O
-	O
acting	O
antivirals	O
.	O

Asunaprevir	O
is	O
an	O
inhibitor	O
of	I:C4049839
the	I:C4049839
hepatitis	I:C4049839
C	I:C4049839
virus	I:C4049839
(	I:C4049839
HCV	I:C4049839
)	I:C4049839
NS3	I:C4049839
/	I:C4049839
4A	I:C4049839
protease	I:C4049839
,	O
demonstrating	O
efficacy	O
in	O
clinical	O
studies	I:C0008972
in	O
patients	O
infected	B:C0439663
with	O
HCV	O
genotype	I:C3532919
1	I:C3532919
or	O
4	O
,	O
with	O
either	O
peginterferon	O
/	O
ribavirin	O
or	O
combinations	O
of	O
direct	O
-	O
acting	O
antivirals	O
.	O

Asunaprevir	O
is	O
an	O
inhibitor	O
of	I:C4049839
the	I:C4049839
hepatitis	I:C4049839
C	I:C4049839
virus	I:C4049839
(	I:C4049839
HCV	I:C4049839
)	I:C4049839
NS3	I:C4049839
/	I:C4049839
4A	I:C4049839
protease	I:C4049839
,	O
demonstrating	O
efficacy	O
in	O
clinical	O
studies	I:C0008972
in	O
patients	O
infected	O
with	O
HCV	B:C3532919
genotype	I:C3532919
1	I:C3532919
or	O
4	O
,	O
with	O
either	O
peginterferon	O
/	O
ribavirin	O
or	O
combinations	O
of	O
direct	O
-	O
acting	O
antivirals	O
.	O

Asunaprevir	O
is	O
an	O
inhibitor	O
of	I:C4049839
the	I:C4049839
hepatitis	I:C4049839
C	I:C4049839
virus	I:C4049839
(	I:C4049839
HCV	I:C4049839
)	I:C4049839
NS3	I:C4049839
/	I:C4049839
4A	I:C4049839
protease	I:C4049839
,	O
demonstrating	O
efficacy	O
in	O
clinical	O
studies	I:C0008972
in	O
patients	O
infected	O
with	O
HCV	O
genotype	I:C3532919
1	I:C3532919
or	O
4	B:C3532922
,	O
with	O
either	O
peginterferon	O
/	O
ribavirin	O
or	O
combinations	O
of	O
direct	O
-	O
acting	O
antivirals	O
.	O

Asunaprevir	O
is	O
an	O
inhibitor	O
of	I:C4049839
the	I:C4049839
hepatitis	I:C4049839
C	I:C4049839
virus	I:C4049839
(	I:C4049839
HCV	I:C4049839
)	I:C4049839
NS3	I:C4049839
/	I:C4049839
4A	I:C4049839
protease	I:C4049839
,	O
demonstrating	O
efficacy	O
in	O
clinical	O
studies	I:C0008972
in	O
patients	O
infected	O
with	O
HCV	O
genotype	I:C3532919
1	I:C3532919
or	O
4	O
,	O
with	O
either	O
peginterferon	B:C0982327
/	O
ribavirin	O
or	O
combinations	O
of	O
direct	O
-	O
acting	O
antivirals	O
.	O

Asunaprevir	O
is	O
an	O
inhibitor	O
of	I:C4049839
the	I:C4049839
hepatitis	I:C4049839
C	I:C4049839
virus	I:C4049839
(	I:C4049839
HCV	I:C4049839
)	I:C4049839
NS3	I:C4049839
/	I:C4049839
4A	I:C4049839
protease	I:C4049839
,	O
demonstrating	O
efficacy	O
in	O
clinical	O
studies	I:C0008972
in	O
patients	O
infected	O
with	O
HCV	O
genotype	I:C3532919
1	I:C3532919
or	O
4	O
,	O
with	O
either	O
peginterferon	O
/	O
ribavirin	B:C0035525
or	O
combinations	O
of	O
direct	O
-	O
acting	O
antivirals	O
.	O

Asunaprevir	O
is	O
an	O
inhibitor	O
of	I:C4049839
the	I:C4049839
hepatitis	I:C4049839
C	I:C4049839
virus	I:C4049839
(	I:C4049839
HCV	I:C4049839
)	I:C4049839
NS3	I:C4049839
/	I:C4049839
4A	I:C4049839
protease	I:C4049839
,	O
demonstrating	O
efficacy	O
in	O
clinical	O
studies	I:C0008972
in	O
patients	O
infected	O
with	O
HCV	O
genotype	I:C3532919
1	I:C3532919
or	O
4	O
,	O
with	O
either	O
peginterferon	O
/	O
ribavirin	O
or	O
combinations	B:C0013162
of	O
direct	O
-	O
acting	O
antivirals	O
.	O

Because	O
of	O
preferential	B:C1378698
distribution	I:C1378698
of	O
asunaprevir	O
to	O
the	O
liver	O
via	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
(	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
)	O
-	O
mediated	O
transport	O
,	O
asunaprevir	O
demonstrates	O
high	O
apparent	O
oral	O
clearance	O
and	O
very	O
low	O
plasma	O
concentrations	O
.	O

Because	O
of	O
preferential	O
distribution	I:C1378698
of	O
asunaprevir	B:C3491974
to	O
the	O
liver	O
via	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
(	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
)	O
-	O
mediated	O
transport	O
,	O
asunaprevir	O
demonstrates	O
high	O
apparent	O
oral	O
clearance	O
and	O
very	O
low	O
plasma	O
concentrations	O
.	O

Because	O
of	O
preferential	O
distribution	I:C1378698
of	O
asunaprevir	O
to	O
the	O
liver	B:C0023884
via	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
(	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
)	O
-	O
mediated	O
transport	O
,	O
asunaprevir	O
demonstrates	O
high	O
apparent	O
oral	O
clearance	O
and	O
very	O
low	O
plasma	O
concentrations	O
.	O

Because	O
of	O
preferential	O
distribution	I:C1378698
of	O
asunaprevir	O
to	O
the	O
liver	O
via	O
organic	B:C0949791
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
(	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
)	O
-	O
mediated	O
transport	O
,	O
asunaprevir	O
demonstrates	O
high	O
apparent	O
oral	O
clearance	O
and	O
very	O
low	O
plasma	O
concentrations	O
.	O

Because	O
of	O
preferential	O
distribution	I:C1378698
of	O
asunaprevir	O
to	O
the	O
liver	O
via	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
(	O
organic	B:C0949791
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
)	O
-	O
mediated	O
transport	O
,	O
asunaprevir	O
demonstrates	O
high	O
apparent	O
oral	O
clearance	O
and	O
very	O
low	O
plasma	O
concentrations	O
.	O

Because	O
of	O
preferential	O
distribution	I:C1378698
of	O
asunaprevir	O
to	O
the	O
liver	O
via	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
(	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
)	O
-	O
mediated	O
transport	O
,	O
asunaprevir	B:C3491974
demonstrates	O
high	O
apparent	O
oral	O
clearance	O
and	O
very	O
low	O
plasma	O
concentrations	O
.	O

Because	O
of	O
preferential	O
distribution	I:C1378698
of	O
asunaprevir	O
to	O
the	O
liver	O
via	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
(	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
)	O
-	O
mediated	O
transport	O
,	O
asunaprevir	O
demonstrates	O
high	O
apparent	O
oral	B:C0226896
clearance	O
and	O
very	O
low	O
plasma	O
concentrations	O
.	O

Asunaprevir	B:C3491974
plasma	O
concentrations	O
are	O
markedly	O
increased	O
by	O
single	O
-	O
dose	O
rifampin	O
(	O
an	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
inhibitor	O
)	O
and	O
in	O
subjects	O
with	O
moderate	O
to	O
severe	O
hepatic	O
impairment	I:C0948807
.	O

Asunaprevir	O
plasma	O
concentrations	O
are	O
markedly	O
increased	O
by	O
single	O
-	O
dose	O
rifampin	B:C0035608
(	O
an	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
inhibitor	O
)	O
and	O
in	O
subjects	O
with	O
moderate	O
to	O
severe	O
hepatic	O
impairment	I:C0948807
.	O

Asunaprevir	O
plasma	O
concentrations	O
are	O
markedly	O
increased	O
by	O
single	O
-	O
dose	O
rifampin	O
(	O
an	O
organic	B:C0949791
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
inhibitor	O
)	O
and	O
in	O
subjects	O
with	O
moderate	O
to	O
severe	O
hepatic	O
impairment	I:C0948807
.	O

Asunaprevir	O
plasma	O
concentrations	O
are	O
markedly	O
increased	O
by	O
single	O
-	O
dose	O
rifampin	O
(	O
an	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
inhibitor	O
)	O
and	O
in	O
subjects	B:C0080105
with	O
moderate	O
to	O
severe	O
hepatic	O
impairment	I:C0948807
.	O

Asunaprevir	O
plasma	O
concentrations	O
are	O
markedly	O
increased	O
by	O
single	O
-	O
dose	O
rifampin	O
(	O
an	O
organic	O
anion	I:C0949791
-	I:C0949791
transporting	I:C0949791
polypeptide	I:C0949791
inhibitor	O
)	O
and	O
in	O
subjects	O
with	O
moderate	O
to	O
severe	O
hepatic	B:C0948807
impairment	I:C0948807
.	O

In	O
addition	O
,	O
modestly	O
higher	O
plasma	O
concentrations	O
of	O
asunaprevir	B:C3491974
have	O
been	O
noted	O
in	O
subjects	O
infected	O
with	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
relative	O
to	O
healthy	O
subjects	I:C1708335
and	O
in	O
Asian	O
subjects	O
relative	O
to	O
whites	O
.	O

In	O
addition	O
,	O
modestly	O
higher	O
plasma	O
concentrations	O
of	O
asunaprevir	O
have	O
been	O
noted	O
in	O
subjects	B:C0080105
infected	O
with	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
relative	O
to	O
healthy	O
subjects	I:C1708335
and	O
in	O
Asian	O
subjects	O
relative	O
to	O
whites	O
.	O

In	O
addition	O
,	O
modestly	O
higher	O
plasma	O
concentrations	O
of	O
asunaprevir	O
have	O
been	O
noted	O
in	O
subjects	O
infected	B:C0439663
with	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
relative	O
to	O
healthy	O
subjects	I:C1708335
and	O
in	O
Asian	O
subjects	O
relative	O
to	O
whites	O
.	O

In	O
addition	O
,	O
modestly	O
higher	O
plasma	O
concentrations	O
of	O
asunaprevir	O
have	O
been	O
noted	O
in	O
subjects	O
infected	O
with	O
hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
relative	O
to	O
healthy	O
subjects	I:C1708335
and	O
in	O
Asian	O
subjects	O
relative	O
to	O
whites	O
.	O

In	O
addition	O
,	O
modestly	O
higher	O
plasma	O
concentrations	O
of	O
asunaprevir	O
have	O
been	O
noted	O
in	O
subjects	O
infected	O
with	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
relative	O
to	O
healthy	B:C1708335
subjects	I:C1708335
and	O
in	O
Asian	O
subjects	O
relative	O
to	O
whites	O
.	O

In	O
addition	O
,	O
modestly	O
higher	O
plasma	O
concentrations	O
of	O
asunaprevir	O
have	O
been	O
noted	O
in	O
subjects	O
infected	O
with	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
relative	O
to	O
healthy	O
subjects	I:C1708335
and	O
in	O
Asian	B:C0078988
subjects	O
relative	O
to	O
whites	O
.	O

In	O
addition	O
,	O
modestly	O
higher	O
plasma	O
concentrations	O
of	O
asunaprevir	O
have	O
been	O
noted	O
in	O
subjects	O
infected	O
with	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
relative	O
to	O
healthy	O
subjects	I:C1708335
and	O
in	O
Asian	O
subjects	B:C0080105
relative	O
to	O
whites	O
.	O

In	O
addition	O
,	O
modestly	O
higher	O
plasma	O
concentrations	O
of	O
asunaprevir	O
have	O
been	O
noted	O
in	O
subjects	O
infected	O
with	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
relative	O
to	O
healthy	O
subjects	I:C1708335
and	O
in	O
Asian	O
subjects	O
relative	O
to	O
whites	B:C0080105
.	O

At	O
the	O
marketed	O
dose	O
,	O
infrequent	O
hepatic	B:C0205054
transaminase	O
abnormalities	O
were	O
poorly	O
predicted	O
by	O
plasma	O
concentrations	O
.	O

At	O
the	O
marketed	O
dose	O
,	O
infrequent	O
hepatic	O
transaminase	B:C0002594
abnormalities	O
were	O
poorly	O
predicted	O
by	O
plasma	O
concentrations	O
.	O

At	O
the	O
marketed	O
dose	O
,	O
infrequent	O
hepatic	O
transaminase	O
abnormalities	B:C0151625
were	O
poorly	O
predicted	O
by	O
plasma	O
concentrations	O
.	O

For	O
a	O
compound	O
with	O
these	O
characteristics	O
,	O
hepatic	B:C0205054
concentrations	O
may	O
have	O
provided	O
an	O
improved	O
understanding	O
of	O
the	O
in	O
vivo	I:C1515655
pharmacokinetic	O
and	O
pharmacodynamic	O
data	O
to	O
support	O
decision	O
making	O
during	O
development	O
.	O

For	O
a	O
compound	O
with	O
these	O
characteristics	O
,	O
hepatic	O
concentrations	O
may	O
have	O
provided	O
an	O
improved	O
understanding	O
of	O
the	O
in	B:C1515655
vivo	I:C1515655
pharmacokinetic	O
and	O
pharmacodynamic	O
data	O
to	O
support	O
decision	O
making	O
during	O
development	O
.	O

For	O
a	O
compound	O
with	O
these	O
characteristics	O
,	O
hepatic	O
concentrations	O
may	O
have	O
provided	O
an	O
improved	O
understanding	O
of	O
the	O
in	O
vivo	I:C1515655
pharmacokinetic	B:C0201734
and	O
pharmacodynamic	O
data	O
to	O
support	O
decision	O
making	O
during	O
development	O
.	O

For	O
a	O
compound	O
with	O
these	O
characteristics	O
,	O
hepatic	O
concentrations	O
may	O
have	O
provided	O
an	O
improved	O
understanding	O
of	O
the	O
in	O
vivo	I:C1515655
pharmacokinetic	O
and	O
pharmacodynamic	B:C1709518
data	O
to	O
support	O
decision	O
making	O
during	O
development	O
.	O

For	O
a	O
compound	O
with	O
these	O
characteristics	O
,	O
hepatic	O
concentrations	O
may	O
have	O
provided	O
an	O
improved	O
understanding	O
of	O
the	O
in	O
vivo	I:C1515655
pharmacokinetic	O
and	O
pharmacodynamic	O
data	O
to	O
support	O
decision	O
making	O
during	O
development	B:C0872152
.	O

